TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr
Summary
TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREM2 ANTIBODIES AND USES THEREOF
Application US20260092111A1 Kind: A1 Apr 02, 2026
Inventors
Michael FASSLER, Jacob GEORGE
Abstract
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). The anti-TREM2 antibodies or antigen-binding fragments thereof are useful, for example, in detecting TREM2 and in treating neurodegenerative diseases.
CPC Classifications
C07K 16/2803 A61P 25/28 A61P 29/00 A61K 2039/505 C07K 2317/24 C07K 2317/565 C07K 2317/76 C07K 2317/92
Filing Date
2025-06-10
Application No.
19234052
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.